Takeda Pharmaceutical, Eisai, and Nippon Chemiphar offeredearly retirement programs over the past year, a Jiho survey revealed. It appears that not all of them are looking at downsizing, however, with some aggressively seeking to “rejuvenate” their employees by replacing ones…
COLUMN
Maurer's Healthcare Insight (100)
Foreign Pharma Challenges in JapanP. Reed Maurer The penetration of Japan's pharma market by foreign firms continues apace. Growth rates exceed market growth and robust pipelines presage continued market share gains, largely at the expense of mid-sized Japanese firms.Emerging foreign…
To read the full story
COLUMN
- Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
- Do You Attract or Repel Winning Candidates?
April 16, 2021
- The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
- Bring Your A-Game to Your Next Video Call
March 11, 2021
- What Personal Biases Influence Your Hires?
February 19, 2021
The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…